GALMED PHARMACEUTICALS LTD
GLMDNASDAQTrading Snapshot
- Day Range
- $4.59 – $4.66
- 52-Week Range
- $3.29 – $13.20
- Volume
- $3.20B
- Avg Volume
- $3.93B
- Shares Outstanding
- 1.0M
- Next Earnings
- Oct 31, 2026
Fundamentals Snapshot
- Annual Revenue
- $1M
- Last Q Revenue
- $270,547
- P/E Ratio
- -0.3
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-11.91
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +66.7%
Why Investors Own GLMD
- ✓High-growth profile — revenue up +16.6% YoY with expanding US Equity exposure.
- ✓Healthy economics — 26% gross margin and 23% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
GALMED PHARMACEUTICALS LTD
GLMD
StockOtter · stockotter.spaceAbout GALMED PHARMACEUTICALS LTD
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Galmed Pharmaceuticals Becomes EoCene, Unveiling New Ticker Symbol "EOCN" to Reflect its New Dawn Platform for GI Innovation
Standby Equity Purchase Agreement (SEPA) with YA II PN, LTD. (Yorkville) will be terminated effective immediately The Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rul
Galmed Pharmaceuticals (NASDAQ:GLMD) Stock Price Crosses Above Fifty Day Moving Average – Time to Sell?
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD - Get Free Report) shares crossed above its 50 day moving average during trading on Wednesday. The stock has a 50 day moving average of $4.53 and traded as high as $5.4501. Galme
Galmed Announces Successful First-in-Human Proof-of-Concept Clinical Study Results for Colospan's Novel Intraoperative Tissue Assessment Technology
The prospective, single-arm study enrolled 32 colorectal cancer patients at three leading clinical centers in Israel. The primary objective was to demonstrate feasibility of intraoperative quantitative measurement of col
Galmed Announces First Time Results in Prostate Oncology Studies: Aramchol Demonstrates 3-4 Fold Increase in Cell Death Compared to Enzalutamide (XTANDI®) Alone in Prostate Cancer Models
Xtandi® (enzalutamide) is indicated as monotherapy for the treatment of patients with non-metastatic prostate cancer (nmCSPC) at high risk of metastasis and for the treatment of patients with metastatic prostate cancer (
Galmed Pharmaceuticals (NASDAQ:GLMD) Shares Cross Below 200-Day Moving Average – Time to Sell?
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD - Get Free Report) shares passed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $0.62 and traded as low as $0.5753. Galmed P
Galmed Announces Breakthrough Development of Dispersible Film Delivery (ODF), Brain Penetrating formulation of its SCD1 inhibitor Aramchol for Parkinson's Disease, Targeting $6 Billion Market
Aramchol meglumine is the only SCD1 inhibitor with an established clinical safety profile and confirmed blood-brain barrier (BBB) penetration. In order to improve patient convenience and long-term treatment adherence by